Drug intelligence / Profile preview

YKP-1358

Development stage: Discontinued
Lead developer: SK Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

YKP-1358 is a novel investigational atypical antipsychotic small molecule developed by SK Biopharmaceuticals Co., Ltd. It functions as an antagonist at serotonin 5-HT2A and 5-HT2C receptors, and dopamine D2 and D3 receptors. Preclinical studies indicated its potential efficacy in treating both positive and negative symptoms of schizophrenia with a low propensity for extrapyramidal side effects. It progressed to Phase 1 clinical trials for schizophrenia in the United States before its development was discontinued.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on YKP-1358.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YKP-1358.

Explore the full profile